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Understanding the changes in gene expression between stages of
diffuse large B-cell lymphoma
Rachel Skabelund, Dr. Stephen Piccolo, Dr. Kim O’Neill

Introduction

Results

Interestingly, the GSOA analysis revealed more significant
changes between stages I and II than between other
stages. In these gene sets, there were a number of genes
that had already been tied to DLBCL, such as IRF7, IRF9,
and STAT2. These genes are a part of the type I interferon
response, and other researchers have used this pathway
as a treatment target. Our findings suggest that changes
in these genes are happening between stages I and II, and
as further research elucidates how they change, it could
lead to more therapeutic insights for stage I and II DLBCL.
Between stages I and IV, we found genes that were
already associated with differentiating early and late
stage DLBCL, which validates our findings. The results for
changes in stages III and IV highlighted a number of genes
associated with tumor resistance and hypoxic conditions,
which are prevalent in metastatic cell types. Further
insight into how these late stage genes are changing may
help researchers identify when certain types of tumor
resistance are occurring and subsequently, how to tailor
therapies for those tumor types.

In order to understand how cancer progresses
from one stage to the next, researchers have been
analyzing the changes in gene expression between
stages of various cancers. However, very little of
this type of research has been done on diffuse
large B cell lymphoma (DLBCL), a type of nonHodgkin’s lymphoma that affects 18,000 new
patients each year. Using gene set omics analysis
(GSOA), we analyzed B-cell specific gene
expression pathways in consecutive stages of
diffuse large B-cell lymphoma to understand if
there were specific pathways that changed their
expression from one stage to the next.

Methods
Survival Curve Analysis: Progression-free survival
data was processed in R using the survminer
package. Statistical analyses show significant
differences in survival time between stages of
both staging methods (Ann Arbor Clinical Staging
and IPI Staging).

Future Directions

GSOA Analysis:
Input gene expression data, a set
of genes, and the two stages into
the GSOA algorithm
The GSOA algorithm
attempts to differentiate
between the two stages
using machine learning
If the algorithm can successfully
differentiate between the two
stages using the set of genes,
then further investigation can be
done to understand what genes
are changing and why

PANTHER Analysis: Significant gene sets were
then analyzed in PANTHER (protein classification
system) to determine what types of genes were
the most expressed in those gene sets.

Discussion

(ABOVE) Kaplan-Meier survival curves for both staging
systems of DLBCL. Higher stages (or risk groups) have
significantly worse survival times overall, highlighting how
the different stages must have underlying factors that are
impacting survival rates.
(RIGHT) Gene-specific transcriptional regulators, proteinbinding activity modulators, and metabolite interconversion
enzymes were the most prevalent types of significant genes
that changed between stages I and II.
Metabolite
interconversion
enzymes,
gene-specific
transcriptional regulators, protein modifying enzymes, and
cytoskeletal proteins were the most prevalent types of
significant genes that changed between stages I and IV.
Metabolite
interconversion
enzymes,
gene-specific
transcriptional regulators, and protein modifying enzymes
were the most prevalent types of significant genes that
changed between stages III and IV.

Previous studies have found that DLBCL is made of up two
main subtypes, germinal B-cell (GBC) and activated B-cell
(ABC). These two subtypes originate from different points
in the life of a B-cell, and likely have different molecular
pathways that are affected during tumorigenesis. The
current analysis didn’t differentiate between the two
subtypes, and that could have been a confounding factor
in the experiment. To account for this, further analyses
should be run using only GBC or ABC subtypes, and other
clinical factors such as age, comorbidity, or treatment type
should also be analyzed to determine if these variables
affect gene expression or survival rates.

Key Terms
Ann Arbor Clinical Staging: Defines cancer stage based on
how much it has spread in the body. Stage I shows cancer in
one lymph node, stage II is a cancer in a second location on
the same side of the diaphragm, stage III is cancer in
multiple locations on both sides of the diaphragm, and stage
IV shows cancer spread throughout the body
IPI Staging Method: A newer staging method that includes
cancer location, age of the patient, and other risk factors
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